Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy M. Franzetti, M.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

L.H. Su, T.L. Wu, C.H. Chiu Clinical Microbiology and Infection

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cavallo Clinical Microbiology and Infection

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract A. Torres-Cornejo, O.J.

Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive.

Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection D.K.-H. Wong, J. Fung, C.-K. Lee, W.-K.

L. Boyanova Clinical Microbiology and Infection

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

M. Colafigli, C. Torti, E. M. Trecarichi, L. Albini, A. Rosi, V

L.H. Su, T.L. Wu, C.H. Chiu Clinical Microbiology and Infection

Salvage therapy for multidrug-resistant tuberculosis

Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA)† S. Rusconi, F.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class S. Monge, V.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Quinolone resistance among Shigella spp

R. Cantón Clinical Microbiology and Infection

P. Nordmann, L. Poirel Clinical Microbiology and Infection

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

Prevalence of Toscana virus antibodies in residents of Croatia

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.

Drug-resistant human immunodefiency virus

Clinical Microbiology and Infection

Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage.

Vector control: a cornerstone in the malaria elimination campaign

Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America Á. Holguín, G. Yebra, L. Martín,

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Unexpectedly high prevalence of Treponema pallidum infection in the oral cavity of human immunodeficiency virus-infected patients with early syphilis.

New HCV therapies on the horizon

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Salvage therapy for multidrug-resistant tuberculosis

V Duque, ÁA. Holguín, M. Silvestre, J. GonzÁAlez-Lahoz, V. Soriano

G. Rocheleau, C.J. Brumme, J. Shoveller, V.D. Lima, P.R. Harrigan

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 S. Di Giambenedetto, M. Prosperi, I.

Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant.

The practice of travel medicine in Europe

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

The significance of rhinovirus detection in hospitalized children: clinical, epidemiological and virological features J.C. Rahamat-Langendoen, A. Riezebos-Brilman,

Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up N. Gianotti,

Tuberculosis transmission patterns among Spanish-born and foreign-born populations in the city of Barcelona S. Borrell, G. Tudó, E. Rey, J. González-Martín

C. Tamalet, P. Colson, E. Decroly, C. Dhiver, I. Ravaux, A. Stein, D

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

F. Ceccherini-Silberstein, V. Cento, V. Calvez, C.-F. Perno

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

Presence of sandflies infected with Leishmania infantum and Massilia virus in the Marseille urban area† B. Faucher, R. Piarroux, C. Mary Clinical Microbiology.

G.M. Rossolini, E. Mantengoli Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients N. Gianotti,

W. Eugene Sanders, Christine C. Sanders

Antibiotic resistance patterns of more than clinical Escherichia coli isolates in Southeast Austria, 1998–2013 A. Badura, G. Feierl, G. Pregartner,

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Virology: a scientific discipline facing new challenges

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

Impact of antibiotic restrictions: the patient's perspective

The future of diagnostic bacteriology

Presentation transcript:

Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy M. Franzetti, M. Violin, G. Casazza, G. Meini, A. Callegaro, P. Corsi, F. Maggiolo, A.R. Pignataro, S. Paolucci, N. Gianotti, D. Francisci, R. Rossotti, G. Filice, T. Carli, M. Zazzi, C. Balotta Clinical Microbiology and Infection Volume 18, Issue 3, Pages E66-E70 (March 2012) DOI: 10.1111/j.1469-0691.2011.03740.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Distribution of non-B subtypes detected in 126 patients of the study population. *Other non-B clades were CRF01_AE (n = 5), CRF12_BF (n = 4), CRF06_cpx (n = 4), CRF15_01B (n = 3), CRF10_CD (n = 2), CRF09_cpx (n = 2), CRF13_cpx (n = 1), CRF20_BG (n = 1), CRF28_BF (n = 1), CRF31_BC (n = 1). Clinical Microbiology and Infection 2012 18, E66-E70DOI: (10.1111/j.1469-0691.2011.03740.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Proportions of subjects achieving virological suppression at the median week 12. Proportions of virological suppression are shown among the overall population and naïve or experienced subjects, starting an antiretroviral regimen including a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). Clinical Microbiology and Infection 2012 18, E66-E70DOI: (10.1111/j.1469-0691.2011.03740.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions